Shionogi & Co Margen bruto
¿Qué es el Margen bruto de Shionogi & Co?
El Margen bruto de Shionogi & Co., Ltd. es 83.47%
¿Cuál es la definición de Margen bruto?
El margen bruto es la diferencia entre el ingreso y el costo de los bienes vendidos, dividido por el ingreso y expresado como un porcentaje.
Gross margin is a type of profit margin, specifically a form of profit divided by net revenue. It is generally calculated as the selling price of an item, minus the cost of goods sold (production or acquisition costs, not including indirect fixed costs like rent, or administrative costs). The purpose of margins is to give a description of the gross profit.
Margen bruto de compañías en Sector Health Care en OTC en comparadas con Shionogi & Co
¿Qué hace Shionogi & Co?
Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay for HIV treatment. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, Sleep Apnea Syndrome, and Refractory/unexplainedchronic cough; S-637880 for Neuropathic Low Back Pain; Zuranolone for Depression; SDT-001 for attention-deficit/hyperactivity disorder patients; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for Obesity. In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamouscell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary fibrosis; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; S-0373 for Spinocerebellar ataxia; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19. Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.
Empresas con margen bruto similar a Shionogi & Co
- Alnylam Pharmaceuticals tiene Margen bruto de 83.40%
- Religare Enterprises tiene Margen bruto de 83.41%
- Citrix Systems tiene Margen bruto de 83.41%
- Hunan Nucien Pharmaceutical Co tiene Margen bruto de 83.42%
- PetroTal tiene Margen bruto de 83.44%
- Willow Biosciences tiene Margen bruto de 83.46%
- Shionogi & Co tiene Margen bruto de 83.47%
- Enviro-Serv tiene Margen bruto de 83.48%
- Liquidia Corp tiene Margen bruto de 83.49%
- Churchill China Plc tiene Margen bruto de 83.49%
- Granite Real Estate tiene Margen bruto de 83.50%
- Rambus tiene Margen bruto de 83.51%
- Netcall plc tiene Margen bruto de 83.52%